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Abstract
Exposure of p53 mutated estrogen-receptor-negative MDA-MB231 human breast tumor cells to a pharmacological
concentration of estradiol enhances liposome-mediated uptake and expression of SV-40 luciferase. Unexpectedly, the effect
of estradiol on SV-40 expression is evident even when estradiol exposure occurs after the initial uptake phase; this suggests
that estradiol may influence gene expression by mechanisms other than increasing gene uptake alone, such as altering the
intracellular distribution of the gene. We determined that while uptake of SV-40 luciferase is increased only three-fold by
estradiol, there is a 30-fold increase in the nuclear/cytoplasmic ratio of the gene. In order to demonstrate that the influence of
estradiol on gene uptake and expression is translated into a functional response, the effects of estradiol on the function of an
exogenous gene, in this case the apoptotic function of p53, were assessed in the p53 mutated MDA-MB231 breast tumor cell.
While liposome-mediated delivery of CMV-p53 alone was ineffective in promoting cell death, incubation with estradiol and
the liposomal p53 complex resulted in a two-fold increase in cell killing over that observed in cells transfected with the
corresponding mock vector (empty vector for p53). Evidence that cell killing was occurring through apoptosis included
apoptotic body formation, cell shrinkage and an increase in fluorescence after terminal transferase end-labeling. The capacity
of estradiol to promote apoptosis in MDA-MB231 cells by a p53^liposome complex is likely to be related to the preferential
redistribution of the gene from the cytoplasm to the nucleus which could occur during both the uptake and post-uptake
phases. Consequently, although direct effects on gene expression, and the stability of message and protein cannot be ruled
out, the predominant effect of estradiol in this experimental system appears to be to influence DNA translocation from the
cytoplasm to the cell nucleus. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Both viral and non-viral systems can be utilized
for the delivery of exogenous genes into cells and
are being developed for use in gene therapy [1].
The most widely used non-viral gene delivery system
relies on the use of cationic lipids to form complexes
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with DNA [2], although non-viral delivery systems
are generally relatively ine⁄cient [3]. We have re-
cently reported that the use of pharmacological con-
centrations of estradiol as well as ionizing radiation
can enhance the e⁄ciency of liposomal-mediated
gene uptake and expression in the breast tumor cell
[4,5]. The current studies were performed to deter-
mine how estradiol in£uences select components of
this process including gene uptake, intracellular dis-
tribution between the cytoplasmic and nuclear com-
partments and gene function.
We previously demonstrated [4] that the non-phys-
iological concentration of estradiol used in these
studies could increase gene uptake and expression
in both estrogen-receptor-positive MCF-7 and estro-
gen-receptor-negative MDA-MB231 breast tumor
cells [6]. This ¢nding is consistent with an earlier
report indicating that the e¡ects of pharmacological
concentrations of estradiol are not dependent on the
estrogen-receptor status of the breast tumor cell [7].
The current work is focused exclusively on MDA-
MB231 cells as these cells have mutant p53 [8] and
mutations in p53 have been shown to prevent apop-
tosis [9,10]. Since adenoviral delivery of p53 has been
shown to promote apoptosis in p53 mutant MDA-
MB-231 cells [11], we reasoned that these cells could
be used to assess gene function if the delivery of p53
in the presence of estradiol were to promote apopto-
sis.
The present studies demonstrate that estradiol in-
creases gene uptake, and produces a profound alter-
ation in the intracellular distribution of an exogenous
gene. Furthermore, the function of the exogenous
gene remains intact as these e¡ects of estradiol are
accompanied by the induction of apoptosis when the
exogenous gene delivered to the cell is p53.
2. Materials and methods
2.1. Materials
Dulbecco’s modi¢ed Eagle’s medium (DMEM,
56^439) was obtained from Hazelton Research Prod-
ucts, Denver, PA; L-glutamine, penicillin (10 000 U/
ml), streptomycin (10 mg/ml), and fetal bovine serum
were obtained from Whittaker Bioproducts, Wal-
kersville, MD; de¢ned bovine calf serum was ob-
tained from Hyclone Laboratories, Logan, Utah.
Trypsin-EDTA, lipofectamine, and optiMEM were
obtained from Gibco-BRL (Gaithersburg, MD).
The pSV-40^luciferase (Promega) was kindly pro-
vided by Dr. Phil Hylemon. The p-CMV-p53 and
p-CMV-mock p53 were constructed as previously de-
scribed [9].
2.2. Cell culture
The MDA-MB-231 cells were obtained from Dr.
Eric Westin at the Medical College of Virginia of
Virginia Commonwealth University, Richmond,
VA. Cells were maintained in Dulbecco’s minimal
essential medium (Hazelton Research Products, Den-
ver, PA) supplemented with 5% fetal calf serum (Life
Technologies, Grand Island, NY), 5% de¢ned bovine
serum (Hyclone Laboratories, Logan, UT) glutamine
(29.2 mg/l00 ml), amphotericin B (5 Wg/ml) (Sigma),
and penicillin/streptomycin (0.5 ml/100 ml) (Whit-
taker Bioproducts, Walkersville, MD). Approxi-
mately, 1U104 MDA-MB-231 cells per well were
subcultured in six-well plates and allowed to grow
for 2^3 days so as to achieve 60% con£uency prior
to conducting the gene delivery experiments de-
scribed below.
2.3. Preparation of DNA^liposome complex and
optimization of transfection conditions
The manufacturer’s recommendations were fol-
lowed for DNA^liposome complex preparation and
optimization of the transfection conditions to human
breast cancer cells. Brie£y, DNA was mixed with
lipofectamine in serum free optiMEM media and in-
cubated at room temperature for 45 min with gentle
shaking every 15 min. Optimal conditions for trans-
fection proved to be the use of 6 Wl of lipofectamine.
As 2^4 Wg of DNA per ml gave adequate results, 2 Wg
of DNA (1:1: :SV-40 luciferase: CMV-L-galactosi-
dase) and 6 Wl of lipofectamine [4,5,12] were used
throughout the study.
2.4. Transfection procedure and estradiol co-treatment
Estradiol was dissolved in a mixture of ethanol/
polyethylene glycol (at a ratio of 45:55), a vehicle
non-toxic to human breast cancer cells [13]. MDA-
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MB-231 cells in six well plates were washed with
optiMEM, exposed to the DNA^liposome complex
in the presence of either vehicle or various concen-
trations of estradiol (in a volume of 1 ml) and incu-
bated at 37‡C for 5 h. An additional 1 ml of MEM
media containing 20% serum and either vehicle or
estradiol was added and the incubation continued
overnight at 37‡C. The media was decanted and re-
placed with MEM containing 10% serum and cells
were incubated at 37‡C for the indicated times. In
selected experiments, the cells were exposed to estra-
diol either during the uptake or post-uptake phases,
as well as during both uptake and post-uptake
phases, as shown in Fig. 1.
2.5. Luciferase reporter assay
Cells transfected with DNA were washed twice
with 2 ml PBS, and lysed using 250 Wl/well of report-
er lysis bu¡er (Promega, Madison, WI) containing
125 mM Tris, pH 7.8 with H3PO4, 10 mM EDTA,
10 mM DTT, 50% glycerol and 5% triton X-100,
diluted 1:4 for 15 min at room temperature. The
cell lysate was scraped using a rubber policeman,
collected in 1.5 ml microfuge tubes and centrifuged
at 10 000 rpm for 2 min at 4‡C. The supernatant was
transferred to a 1.5-ml Eppendorf tube and stored at
370‡C prior to the determination of luciferase activ-
ity.
The luciferase activity of the cellular extract was
determined by mixing 20 Wl of cell extract with 100 Wl
of Promega Luciferase reagent containing 270 WM
coenzyme A (lithium salt), 470 WM luciferin, 530
WM ATP, 20 mM tricine, 1.07 mM (MgCO3)
4Mg(OH)2W5H2O, 2.67 mM MgSO4, 0.1 mM
EDTA and 33.3 mM DTT, pH 7.8 at room temper-
ature. Relative light units (RLU) were measured for
20 s in a Berthold LB 9501 luminometer [4,5,10].
In parallel experiments, the transfected cells were
trypsinized to quantitatively evaluate viable cell num-
ber by trypan blue exclusion [14]. The luciferase ac-
tivity was expressed as RLU per viable cell.
2.6. Cell fractionation
For the determination of intracellular distribution
of the transfected gene, the transfected cells were
pelleted and processed as described below. The cells
were labeled with [3H]thymidine at 37‡C for 24 h.
The radioactive media was decanted and the cells
were pelleted and suspended in 1 ml triton based
bu¡er (10 mM Tris-HCl, 10 mM KCl, 1.5 mM
MgCl2, 0.25% triton). Cells were homogenized by
repeated passage (U5) through a 26.5-gauge needle
attached to a 1-ml disposable syringe. The solution
was centrifuged at 10 000 rpm for 10 min. The super-
natant (cytoplasmic fraction) was removed and the
nuclear pellet was resuspended in sucrose based bu¡-
er (0.25 M sucrose, 10 mM NaCl, 10 mM Tris HCl,
1.5 mM MgCl2) together with 150 Wl of detergent
(10% sodium deoxycholate and 10% Tween-40) and
vortexed for 30 s to lyse nuclei. The purity of nuclear
and cytoplasmic fractions were veri¢ed, respectively,
based on radioactive thymidine incorporation by tri-
choloroacetic acid precipitation and colorimetric as-
sessment of lactate dehydrogense enzyme activity.
2.7. Extraction and quantitation of transfected DNA
The luciferase plasmid DNA was extracted from
MDA-MB231 breast cancer cells utilizing the stand-
ard Hirt protocol [15] which extracts low molecular
weight DNA through the preferential precipitation of
cellular DNA in the presence of SDS and NaCl.
Brie£y, the transfected cells were suspended in
0.045 M Tris-borate, 0.001 M EDTA, 0.5% SDS
and 1.6 M sodium chloride and digested overnight
at 4‡C. The cellular extract was pelleted and DNA
was extracted twice with 200 Wl of PCI (phenol/
chloroform/isoamyl alcohol, 25:24:1) and once with
chloroform. The DNA was puri¢ed and precipitated
using two volume of ethanol, 0.02 M sodium chlo-
ride, incubated at 380‡C for 30 min and then pel-
leted at 14 0000 rpm for 15 min at 4‡C. The DNA
was resuspended in an appropriate volume of sterile
water in proportion to the viable cell number so as
to maintain equivalent DNA concentrations in con-
trol and irradiated cells. DNA extracted from ap-
proximately 500 000 cells was loaded into each lane
of an 0.8% agarose gel in TBE bu¡er containing
ethidium bromide, and electrophoresis was per-
formed at 90 mV for 3^4 h. Densitometric analysis
was performed to quantitate the extracted DNA in
each lane.
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2.8. Statistical analysis
All experiments were repeated at least once. The
estradiol-treated cells were compared with controls
by ANOVA; a P-value of 6 0.05 was considered
to be statistically signi¢cant. The statistical analysis
was performed utilizing Statview 512TM McIntosh
statistical software.
3. Results
3.1. In£uence of estradiol exposure during liposome-
mediated gene uptake and post-uptake phases on
gene expression
We have previously reported that exposure of ei-
ther estrogen-receptor positive MCF-7 or estrogen-
receptor negative MDA-MB231 breast tumor cells to
a pharmacological concentration of estradiol in-
creases the expression of luciferase from an SV-40^
luciferase reporter gene transfected into the cells by a
liposome-mediated transfection protocol [4]. These
studies were performed as shown by arrow C in
Fig. 1, with continuous exposure of the cell to estra-
diol during both the uptake phase (when cells are
exposed to the liposomal DNA complex) as well as
during the post-uptake phase (after the liposomal
DNA complex has been withdrawn from the incuba-
tion medium).
Estradiol may in£uence subcellular processes in
cytoplasmic and nuclear compartments[7,16] as well
as cellular membrane stability [17]. Thus, it is possi-
ble that the observed e¡ects of estradiol represent
alterations in the intracellular distribution of the
exogenous gene as well as enhanced gene uptake
across the cell membrane. If this is the case, then
estradiol should be capable of in£uencing gene ex-
pression even during the post-uptake phase, when
e¡ects on uptake across the membrane are likely to
be negligible.
In order to determine whether the in£uence of es-
tradiol on gene expression could be related to trans-
location and expression independent of gene uptake,
we evaluated the e¡ects of estradiol on gene expres-
sion with estradiol exposure during the post-uptake
phase (i.e. after removal of the liposomal complex as
shown by arrow B in Fig. 1). We further compared
the relative e¡ects on gene expression of estradiol
exposure during both the uptake and post-uptake
phases (arrow C in Fig. 1) with estradiol exposure
during either phase (arrows A and B) alone.
Fig. 2 shows that, as expected, luciferase expres-
sion from the SV-40^luciferase reporter gene was in-
creased by exposure to estradiol during the uptake
phase. In addition, a signi¢cant increase in luciferase
expression was also observed upon exposure to es-
tradiol during the post-uptake phase. As would be
expected from these and previous observations [4],
the increase in expression following exposure to es-
tradiol during both the uptake and post-uptake
phases was greater than that with estradiol treatment
during the uptake or post-uptake phases alone.
3.2. In£uence of estradiol on intracellular gene
distribution
The observation that estradiol exposure even dur-
ing the post-uptake phase increases gene expression
Fig. 1. Schematic representation of the protocol for liposomal
gene delivery combined with estradiol in MDA-MB-231 human
breast cancer cells. Phases of gene-delivery: transfection with
the liposomal SV-40^luciferase gene was initiated at time 0 and
continued at 37‡C for 24 h (uptake phase). After the gene for-
mulation was removed and replaced by fresh medium, incuba-
tion was continued for an additional 48 h (post-uptake phase).
After 72 h the cell extract was prepared to evaluate reporter ac-
tivity. Cells were exposed to estradiol during the uptake phase
alone (A), the post-uptake phase alone (B) or during both the
uptake and post-uptake phases (C).
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supports the hypothesis that estradiol is having ef-
fects other than or in addition to enhancing gene
delivery across the cell membrane. In order to deter-
mine how estradiol in£uences levels of the exogenous
gene within the cell as well as its intracellular distri-
bution, cells were transfected with the SV-40^lucifer-
ase^liposomal complex either with or without a 24-h
co-exposure to estradiol. SV-40 luciferase was iso-
lated from whole cell extracts as well as the nuclear
and cytoplasmic fractions. The relative purity of the
cytoplasmic and nuclear fractions was substantiated
by demonstrating that greater than 95% of cellular
lactate dehydrogenase activity was associated with
the cytoplasmic extract and similarly that greater
than 95% of [3H]thymidine incorporation was evi-
dent in the nuclear extract (Fig. 3).
In the representative experiment assessing total
gene uptake into the cell presented in Fig. 4A, cells
treated with estradiol during the uptake phase are
shown to accumulate signi¢cantly higher levels of
the SV-40^luciferase transgene than the correspond-
ing controls transfected with SV-40 luciferase in the
absence of estradiol. Fig. 4B indicates that there was
a 2.8 þ 0.9-fold increase in the delivery of the lucifer-
ase gene by estradiol.
Although there is a signi¢cant increase in gene
uptake, this is clearly insu⁄cient to explain 30-fold
increase in gene expression which occurs as a result
of estradiol exposure during the uptake phase. In the
studies presented in Fig. 5A to establish whether es-
tradiol a¡ects the nuclear to cytoplasmic distribution
of the exogenous transgene, it is evident that estra-
diol essentially reversed this distribution ratio. That
is, a far greater amount of the luciferase gene accu-
mulated into the nucleus of estradiol-treated cells as
compared to those treated with the vehicle control.
Correspondingly, a marked decrease was evident in
cytoplasmic SV-40^luciferase in the estradiol-treated
cells. The alteration in intracellular distribution of
the luciferase gene from the cytoplasm into the nu-
cleus was quite pronounced. Fig. 5B indicates that
there was a 28.8 þ 0.9 fold increase in the nuclear/
cytoplasmic ratio of the SV-40^luciferase which ap-
proximates the increase in gene expression shown in
Fig. 2.
Fig. 3. Cytoplasmic and nuclear fractionation of cells. Lactate
dehydrogenase and [3H]thymidine incorporation were used as
cytoplasmic and nuclear markers for assessing the purity of the
separated fractions from which the exogenously transfected
DNA was extracted (as shown in Fig. 5).
Fig. 2. Improvement of SV-40^luciferase gene expression in
MDA-MB-231 human breast cancer cells following exposure to
100 WM estradiol during the uptake, post-uptake, and uptake/
post-uptake phases. Note that maximal improvement in lucifer-
ase expression occurs following exposure to estradiol during
both the uptake and post-uptake phases.
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3.3. Promotion of apoptotic cell death in
MDA-MB231 breast tumor cells by the
combination of estradiol and the liposomal
p53 complex
The studies described above demonstrate increased
gene uptake, redistribution of the gene from the cy-
toplasm to the nucleus and enhanced gene expression
by estradiol. However, it is necessary to demonstrate
that these e¡ects of estradiol also serve to re-establish
the functional response of the gene and that this
function is pharmacologically signi¢cant. For this
purpose, we chose to assess the capacity of estradiol
to re-establish the apoptotic function of p53, as
MDA-MB231 cells have a mutant p53 gene [8]. We
reasoned that restoration of p53 to these cells might
be su⁄cient to promote apoptotic cell death as has
been shown in other studies where wild-type p53 was
restored to p53 mutant cells [11]. Cells were trans-
fected with either p53 under the control of a constit-
utive CMV promoter or with mock p53 (the plasmid
Fig. 5. Estradiol alters the intracellular distribution of the SV-
40^luciferase gene in MDA-MB-231 human breast cancer cells.
Cells were exposed to 100 WM estradiol and the liposomal SV-
40^luciferase complex for 24 h. (A) SV-40^luciferase plasmids
extracted from cytoplasmic and nuclear fractions. (B) The nu-
clear/cytoplasmic ratio for the luciferase gene in two separate
experiments þ S.E.M.
Table 1
Re-establishing p53-mediated cell death in MDA-MB-231 cells.
MDA-MB-231 cells were treated with the liposomal p53 com-
plex and then continuously exposed to estradiol (100 WM) dur-
ing uptake and post-uptake phases:
Treatment
Chemical Gene Dead Cells (%)a
None p53 31.5 þ 0.2
Vehicle Mock p53 36.6 þ 9.4
Vehicle p53 31.5 þ 0.2
Estradiol Mock p53 40.5 þ 0.2
Estradiol p53 80.2 þ 3.8b
aValues represent the means of duplicate samples.
bThis value was signi¢cantly higher than all other samples
(p6 0.05).
Fig. 4. Estradiol improves delivery of the SV-40^luciferase gene
in MDA-MB-231 human breast cancer cells. Cells were exposed
to 100 WM estradiol and the liposomal SV-40^luciferase com-
plex for 24 h. (A) SV-40^luciferase plasmids isolated from the
entire cells and separated by agarose gel electrophoresis. (B)
The extent of improvement in luciferase gene delivery from
three di¡erent experiments þ S.E.M.
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originally used for cloning the p53 construct) using
the standard Lipofectamine transfection protocol,
but without estradiol treatment. Table 1 indicates
that there was no di¡erence in the extent of cell
death (30^35% of the cell population) in the absence
or presence of p53 under these experimental condi-
tions (i.e. transfection in the absence of estradiol).
We concluded that the observed toxicity was related
to the transfection protocol and that p53 was not
in£uencing cell viability. The lack of a functional
p53 response was likely to be due to insu⁄cient levels
of the gene within the cell or limited distribution of
the gene to the nucleus.
Consequently, cells transfected with the liposome^
p53 were incubated with estradiol during both the
uptake and post-uptake phases in order to both in-
Fig. 6. Fluorescent staining (TUNEL assay) and morphological evaluation (phase contrast microscopy) of apoptotic cell death in
MDA-MB-231 human breast cancer. Cells were treated with the liposomal CMV-p53 gene complex and estradiol (100 WM) during
both the uptake and post-uptake phases. For the TUNEL assay, cells were incubated with £uorescent labeled antibodies. For morpho-
logical evaluation, cells were incubated with Geimsa^Wright stain. Note formation of apoptotic bodies (arrowhead) in the cells treated
with both estradiol and the p53 gene (A). These typical characteristics of apoptosis were negligible in the cells treated with estradiol/
mock p53 (B), vehicle/p53 (C) or vehicle/mock p53 (D).
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crease levels of the gene within the cell and to en-
hance its translocation to the nucleus. Under these
conditions, cells transfected with p53 demonstrated a
marked enhancement of cell killing. Table 1 indicates
that incubation with estradiol essentially doubled the
number of non-viable cells as compared to transfec-
tion with p53 in the absence of estradiol. Although
exposure to estradiol during either the uptake or
post-uptake phases alone signi¢cantly enhances re-
porter transgene expression (as shown in Fig. 2), nei-
ther of these approaches was su⁄cient for the induc-
tion of apoptosis (data not shown).
To ascertain that cell death which occurred after
transfection with p53 in the presence of estradiol was
indeed related to an apoptotic mechanism, we eval-
uated various morphological and biochemical indica-
tors of apoptosis. As shown in Fig. 6, phase contrast
microscopy clearly indicated the presence of shrunk-
en cells and apoptotic nuclear bodies after treatment
with estradiol and transfection with p53. These char-
acteristics were negligible in the MDA-MB-231 cells
treated with estradiol and a mock p53 vector (panel
B), the vehicle and p53 (panel C), or with vehicle and
mock p53 vectors (panel D). Similarly, the TUNEL
assay demonstrated an intense £uorescent signal in
the MDA-MB-231 cells treated with estradiol and
p53 (panel A), which was not evident for any of
the other experimental condition.
4. Discussion
Previous studies in this laboratory [4] have demon-
strated that pharmacological concentrations of estra-
diol increase the expression of genes delivered by a
liposome-mediated protocol in both estrogen-recep-
tor-positive MCF-7 and estrogen-receptor-negative
MDA-MB231 breast tumor cells [6]. These observa-
tions indicate that the e¡ects of a supra-physiological
concentration of estradiol on gene uptake and ex-
pression in the breast tumor cell is independent of
estrogen-receptor status. In the current work, we
have further established that the mechanism for im-
proving transgene expression by estradiol includes its
in£uence on gene uptake across the cell membrane as
well as redistribution of the transgene from the cy-
toplasm into the nucleus. In fact, the most pro-
nounced e¡ect of estradiol appears to be the 30-
fold increase in the nuclear to cytoplasmic ratio
rather than the 2^3-fold increase in gene uptake.
The capacity of estradiol to alter the nuclear to cy-
toplasmic distribution of the gene is further sup-
ported (albeit indirectly) by the observation that es-
tradiol enhances gene expression during the post-
uptake phase ^ when transport of the gene across
the cell membrane is expected to be negligible.
A number of mechanisms could be responsible for
the e¡ects of estradiol on transmembrane gene trans-
port, the redistribution of the transgene between the
nuclear and cytoplasmic compartments and the en-
hancement of gene expression. These include e¡ects
on cell membrane stability [17], deregulation of ions
such as calcium [16], alteration in the nuclear mem-
brane [16] and of cyto/nuclear-skeletal proteins
[7,18]. Estradiol could also in£uence the function of
the exogenous gene at the transcriptional level by
stimulating activity of the promoter, post-transcrip-
tionally at the level of mRNA stability or at the
translational and post-translational levels, respec-
tively, by increasing protein synthesis or the stability
of the expressed protein.
It is of interest that apoptotic cell death could not
be re-established simply through liposomal-mediated
delivery of the p53 transgene to the MDA-MB231
cells. This could be related to the fact that most of
the exogenous DNA is localized to the cytoplasmic
fraction. However, when cells were exposed to estra-
diol during either the uptake or post-uptake phases
alone, the liposomal p53 complex failed to promote
apoptosis. This suggests that despite the e¡ects of
estradiol on the redistribution of the gene from the
cytoplasm to the nucleus, there may still have been
insu⁄cient p53 in the cell to promote apoptosis. In
contrast, when MDA-MB231 cells were exposed to
100 WM estradiol both immediately upon transfec-
tion with p53 as well as during the post-uptake
phase, the cells apparently underwent apoptotic cell
death. Thus, it appears that a threshold level of nu-
clear p53 gene expression may be required for the
promotion of apoptotic cell death.
In summary, these studies indicate that exposure
of the breast tumor cell to a pharmacological con-
centration of estradiol increases the liposome-medi-
ated uptake, cytoplasmic to nuclear translocation,
expression and function of an exogenous gene in
the breast tumor cell. Therefore, estradiol has the
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capacity to alter fundamental aspects of cell function
through estrogen-receptor-independent mechanisms.
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